Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED95 of single-dose remimazolam for preoperative sedation in obese vs nonobese pediatric OSA patients
ChiCTR2400085070Phase 4Completed
- Sponsor
- Shanghai Children's Medical Center
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Adequate sedation (RSS ≥4 at 3 minutes after remimazolam bolus). Started May 2024; status: completed.
02
Drugs
remimazolam
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ChiCTR2400085070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085070.